Veradermics, Incorporated (MANE) Stock Forecast
MANE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 7 analysts
- Price target
- $163.50 average of analyst targets
- Upside to target
- +50.2% from the latest close
- Next earnings
- November 10, 2026 EPS estimate $-0.59
- 52-week range
- $37.03 – $130.90
MANE analyst ratings
7 analystsNumber of analysts at each rating.
MANE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MANE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.60 | −$0.74 | −$0.51 | — | — | 5 |
| Current fiscal year (2026) | −$2.89 | −$3.12 | −$2.61 | −$111.91 | +97.4% | 5 |
| Next fiscal year (2027) | −$2.69 | −$3.14 | −$2.00 | −$2.89 | +6.7% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MANE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $8.7M | $0 | $51.9M | 0.0% | 6 |
MANE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MANE revenue: reported and forecast
MANE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.64 | −$0.59 | −$0.59 | −$0.59 | −$0.60 | −7.0% | 2 up · 0 down |
| Current fiscal year (2026) | −$2.84 | −$2.94 | −$2.94 | −$2.87 | −$2.89 | +1.7% | 2 up · 0 down |
| Next fiscal year (2027) | −$3.05 | −$2.69 | −$2.69 | −$2.69 | −$2.69 | −11.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MANE earnings surprises
Reported EPS vs the consensus estimate for the last 3 quarters; MANE beat in 2 of 3.
What analysts expect from MANE
7 analysts cover Veradermics; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $163.50, 50.2% above the latest close of $108.82. Analysts expect earnings of −$2.89 per share for 2026, +97.4% from a year earlier. For 2027 the average estimate is −$2.69 per share on revenue of $8.7 million. Veradermics beat the EPS estimate in 2 of the last 3 quarters.
Related: MANE income statement, MANE key metrics, MANE chart. See the MANE stock overview for the latest quote and news.
MANE forecast FAQ
What is Veradermics's price target?
The average analyst price target for Veradermics is $163.50, 50.2% above the latest close of $108.82.
Is Veradermics a buy, hold or sell?
Of 7 analysts covering Veradermics, 6 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Veradermics's EPS forecast?
Analysts forecast −$2.89 per share for 2026 (range −$3.12 to −$2.61); for 2027 the estimate is −$2.69.
When does Veradermics report earnings?
Veradermics is expected to report results for the quarter ending September 30, 2026 on November 10, 2026; the EPS estimate is $-0.59.
Does Veradermics usually beat earnings estimates?
Veradermics reported EPS at or above the analyst estimate in 2 of the last 3 quarters.